PCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemia

Archive ouverte

Alonso, Rodrigo | Mata, Pedro | Muniz, Ovidio | Fuentes-Jimenez, Francisco | Diaz, Jose Luis | Zambon, Daniel | Tomas, Marta | Martin, Cesar | Moyon, Thomas | Croyal, Mickael | Thedrez, Aurélie | Lambert, Gilles

Edité par CCSD ; Elsevier -

Background and aims: We aimed to assess whether elevated PCSK9 and lipoprotein (a) [Lp(a)] levels associate with coronary artery calcification (CAC), a good marker of atherosclerosis burden, in asymptomatic familial hypercholesterolemia. Methods: We selected 161 molecularly defined FH patients treated with stable doses of statins for more than a year. CAC was measured using the Agatston method and quantified as categorical variable. Fasting plasma samples were collected and analyzed for lipids and lipoproteins. PCSK9 was measured by ELISA, Lp(a) and apolipoprotein (a) concentrations by inmunoturbidimetry and LC-MS/MS, respectively. Results: Circulating PCSK9 levels were significantly reduced in patients without CAC (n = 63), compared to those with CAC (n = 99). Patients with the highest CAC scores (above 100) had the highest levels of circulating PCSK9 and Lp(a). In multivariable regression analyses, the main predictors for a positive CAC score was age and sex followed by circulating PCSK9 and Lp(a) levels. Conclusions: In statin treated asymptomatic FH patients, elevated PCSK9 and Lp(a) levels are independently associated with the presence and severity of CAC, a good predictor of coronary artery disease.

Consulter en ligne

Suggestions

Du même auteur

Plasma PCSK9 measurement by liquid chromatography-Tandem mass spectrometry and comparison with conventional ELISA

Archive ouverte | Croyal, Mickael | CCSD

The combination of liquid chromatography-tandem mass spectrometry (LC-MS/MS) and trypsin proteolysis is an effective tool for accurate quantitation of multiple proteins in a single run. However, expensive samples pre-treatment as ...

Proprotein convertase subtilisin kexin type 9 inhibition for autosomal recessive hypercholesterolemiabrief report

Archive ouverte | Thedrez, Aurélie | CCSD

Objective Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors lower low-density lipoprotein (LDL) cholesterol in the vast majority of patients with autosomal dominant familial hypercholesterolemia. Will PCSK9 inhibiti...

Alirocumab efficiently reduces LP(A) levels by lowering Apolipoprotein (A) [APO(A)] production rate in Non-Human primates (NHP)

Archive ouverte | Croyal, Mickael | CCSD

International audience

Chargement des enrichissements...